Advertisement

Pegaptanib: choroidal neovascularization in patients with age-related macular degeneration and previous arterial thromboembolic events

Abstract

Purpose

To evaluate the efficacy and the rate of side effects of the pegylated aptamer pegaptanib in the treatment of patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and a history of previous arterial thromboembolic events (ATEs).

Methods

Twenty-three eyes of 23 patients with subfoveal CNV due to AMD and cerebrovascular accidents (n = 12) and myocardial infarction (n = 11) in the previous 6 months received intravitreal pegaptanib 0.3 mg according to a pro re nata regimen and were followed for 12 months. The paired Student t test was used to evaluate mean changes in best-corrected visual acuity (BCVA; primary outcome measure) and central foveal thickness (CFT).

Results

The mean patient age was 71.5 ± 4.6 years; there were 14 women and 9 men. The CNV was type 1, 2, and 3 in 18, 3, and 2 eyes, respectively. The mean BCVA improved from 0.67 ± 0.23 logMAR at baseline to 0.52 ± 0.31 logMAR at the end of 12-month follow-up (p = 0.044). Thirty-five percent of patients achieved ≥3 Early Treatment Diabetic Retinopathy Study lines improvement at 12 months. Mean CFT at baseline (381 ± 111 µm) decreased to 304 ± 82 µm at 12 months (p = 0.008). Patients received a mean of 4.3 ± 1.3 (range 3-7) injections. No systemic or ocular side effects occurred; no patient experienced further ATEs.

Conclusions

Intravitreal pegaptanib can be considered a viable treatment option for patients with AMD-related CNV who are at high risk of ATEs.

Post author correction

Article Type: ORIGINAL RESEARCH ARTICLE

Article Subject: Retina MED

DOI:10.5301/ejo.5001060

Authors

Maurizio Battaglia Parodi, Emanuele Di Bartolo, Claudia Brue, Ezio Cappello, Claudio Furino, Sebastiano Giuffrida, Manuela Imparato, Michele Reibaldi

Article History

Disclosures

Financial support: No financial support was received for this submission.
Conflict of interest: M.B.P. is a consultant for Bausch & Lomb. None of the other authors has conflict of interest with this submission.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  •  Department of Ophthalmology, Ospedale San Raffaele, Milan - Italy
  •  Department of Ophthalmology, Azienda Ospedaliero-Universitaria Pisana, Pisa - Italy
  •  Department of Ophthalmology, Polytechnic University of Marche, Ancona - Italy
  •  Department of Ophthalmology, Ospedale San Bassiano, Bassano del Grappa - Italy
  •  Department of Ophthalmology, University of Bari, Bari - Italy
  •  Bausch and Lomb Iom SpA, Vimodrone, Milan - Italy
  •  Department of Ophthalmology, Fondazione IRCCS Policlinico San Matteo, Pavia - Italy
  •  Department of Ophthalmology, University of Catania, Catania - Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.